Company Profile
Company Overview
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world.
Our portfolio of 14 marketed products includes a number of category firsts, including the only complete treatment regimens for HIV infection available in a once-dailysingle pill – Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), approved in 2006, and Complera™, approved in 2011.
Company History
Gilead was founded in 1987 in Foster City, California. In just over 20 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 4,200 employees in offices across four continents.
In 2010, Gilead’s annual revenues reached nearly $8 billion, and in 2009, BusinessWeek ranked Gilead #1 in its annual listing of the 50 Best-Performing Companies.
Benefits
Gilead recognizes outstanding performance with a variety of rewards. Our Total Rewards package helps us to attract and motivate the talent we need to remain competitive in our industry.
The Total Rewards program includes exceptional stock option and employee stock purchase plans, competitive base salary and incentive compensation, health and welfare benefits, 401(k) savings with a company match that vests immediately, and other valuable benefits, such as paid time off and wellness programs.